# A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK0683 in Patients With Advanced Cancer (0683-008)

> **NCT00750178** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 30 (actual)

## Conditions studied

- Cancer, Advanced

## Interventions

- **DRUG:** vorinostat (MK0683 )

## Key facts

- **NCT ID:** NCT00750178
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-11-01
- **Primary completion:** 2005-08-01
- **Final completion:** 2005-11-01
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2017-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00750178

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00750178, "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK0683 in Patients With Advanced Cancer (0683-008)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00750178. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*